Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Daiichi Sankyo, Eli Lilly Apply for Prasugrel in EU
March 3, 2008
- Number of Privately-Operated Pharmacies to be Halved: Mr Urushibata
March 3, 2008
- New GL on Drugs Obtained from Autologous Cells Announced
March 3, 2008
- BUSINESS NEWS IN BRIEF
March 3, 2008
- STATISTICS／Rate of Death due to Liver Cancer Is Third Highest in Japan
March 3, 2008
- Pharmacies Will Lose or Win Depending on How Many Generics They Dispense
March 3, 2008
- Japan Needs to Introduce Medicoeconomic Assessment of Medical Technologies: Prof Kamae
March 3, 2008
- 50-60% of People Want to Use Generics: Survey
March 3, 2008
- REGULATORY NEWS IN BRIEF
March 3, 2008
- Generics Will Be Dispensed for No More Than 10% of Prescriptions: Dr Muto
March 3, 2008
- Need to Enhance R&D Ability of Medical Devices Industry Stressed
March 3, 2008
- TOPICS／Daiichi Sankyo Introduces Stock Compensation-Type Stock Option Plan
March 3, 2008
- NPhA Frustrated with Maintenance of 2 Different Dispensing Fees
March 3, 2008
- Japan's Most Admired Pharma Companies in 2007
March 3, 2008
- Study on Inhibition of Diabetic Progression to Start this Year
March 3, 2008
- Fusion of Technologies from FUJIFILM and Toyama to Enhance R&D
March 3, 2008
- Annual Limit of 25 Cases Proposed for CV Surgery Facilities
March 3, 2008
- Takeda, Merck Serono Drop Matuzumab due to Inefficacy
March 3, 2008
- Real Medical Institution Bankruptcy Crisis Yet to Come
March 3, 2008
- PIII Trial of Nexavar in NSCLC Discontinued: Bayer, Onyx
March 3, 2008
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…